Xeris Biopharma Holdings, Inc. - Common Stock (XERS)

Competitors to Xeris Biopharma Holdings, Inc. - Common Stock (XERS)

Amgen Inc. 

Amgen competes with Xeris Biopharma primarily in the development of biologic therapies. Both companies focus on innovative treatments that address unmet medical needs, particularly in rare diseases and chronic conditions. While Xeris's differentiated formulation technologies provide it with unique product delivery systems for existing compounds, Amgen leverages its extensive pipeline and established reputation in the biotechnology industry, giving it a competitive edge in terms of market reach and funding capabilities.

Civica Rx

Civica Rx aims to address shortages of essential medications by producing generic medications at affordable prices. Although Xeris focuses on biopharmaceuticals with innovative delivery systems, competition comes from Civica as they both attempt to improve patient access to critical medications. Xeris's targeted therapies and unique delivery formats may differentiate its products from Civica's offerings, but Civica's strong commitment to overcoming generic drug shortages allows it to capture segments of the market where Xeris does not compete directly.

Evoke Pharma, Inc. 

Evoke Pharma targets gastrointestinal disorders, similar to some of Xeris's therapeutic areas. The companies compete for the same patient demographics that suffer from nausea and vomiting associated with certain medical conditions. Evoke's current focus on its own unique formulations places it in direct competition with Xeris's proprietary delivery systems. However, Xeris's broader range of applications for its technology may provide it with a wider market potential despite Evoke's more focused product strategy.

Indivior PLC

Indivior specializes in addiction treatment, which aligns with Xeris's focus on therapies for chronic and specialty conditions. The companies compete for market share in niche markets where patient adherence to medication is critical. Xeris's innovative delivery systems may attract patients looking for more manageable treatment options, whereas Indivior has established brand loyalty with its current offerings in the addiction treatment space, giving it a strong foothold in the market.

Sarepta Therapeutics, Inc. 

Sarepta Therapeutics develops innovative treatments for rare genetic diseases, particularly related to neuromuscular disorders. Both Xeris and Sarepta are active in developing therapies that address rare conditions, but Sarepta's advanced gene therapy technologies and more established clinical trials provide it with a significant competitive advantage. Xeris, while also prioritizing innovation, may find it challenging to compete directly with Sarepta's deep pipeline and established reputation in the gene therapy arena.